Price
No data yet.
Social Signal Score
Analyst Ratings
15 analystsRevenue
$171.0K+151.47%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Mani Mohindru
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 31
- Beta
- 1.56
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -16.14
Financials
Revenue
$171.0K+151.5%Net Income
$-8.86MEBITDA
$-8.77MFree Cash Flow
$-9.88MEPS (diluted)
$-0.12Shares Outstanding (diluted)
76.18M+17758.9%Operating Expenses
$0.00Cash & Debt
$33.79MReturn of Capital
$0.00Revenue by Segment (annual)
$366.0KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $593.0K | $-45.85M | $-0.69 |
| 2024 | $683.0K | $-45.43M | $-0.95 |
| 2023 | $488.0K | $-41.44M | $-0.93 |
| 2022 | $386.0K | $-38.70M | $-0.89 |
| 2021 | $359.0K | $-28.29M | $-0.73 |
| 2020 | $366.0K | $-19.31M | $-1.08 |
| 2019 | $244.6K | $-16.41M | $-2.70 |
| 2018 | $378.0K | $-16.46M | $-7.06 |
| 2017 | $505.0K | $-24.91M | $-51.71 |
| 2016 | $381.0K | $-39.20M | $-93.54 |
| 2015 | $313.0K | $-27.47M | $-75.49 |
| 2014 | $280.0K | $-14.32M | $-54.56 |
| 2013 | $259.2K | $-11.81M | $-50.27 |
| 2012 | $450.0K | $-11.57M | $-63.87 |
Valuation
CRDFhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (6)
- Newsseekingalpha.com·6d ago·Neutral
Cardiff Oncology, Inc. (CRDF) Presents at UBS Global Biopharma Conference 2026 Prepared Remarks Transcript Cardiff Oncology, Inc. ( CRDF ) UBS Global Biopharma Conference 2026 November 16, 2026 9:40 AM EST Company Participants Mani Mohindru - President, CEO & Director Conference Call Participants Dejia Zhang Presentation Dejia Zhang Hi, everyone. My name is Dejia Zhang.
View source ↗ - Newsglobenewswire.com·26d ago·Negative
Cardiff Oncology Appoints Leila Alland, MD, as Interim Chief Medical Officer SAN DIEGO, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company targeting RAS-mutated cancer by leveraging PLK1 inhibition, today announced the appointment of Leila Alland, MD, as interim Chief Medical Officer. Dr. Alland is a seasoned biopharmaceutical executive who has led multiple oncology drug development programs.
View source ↗ - Newsglobenewswire.com·32d ago·Negative
… Receives FDA Orphan Drug Designation for Onvansertib in Chronic Myelomonocytic Leukemia SAN DIEGO, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to onvansertib for the treatment of patients with chronic myelomonocytic leukemia (CMML). “CMML remains a difficult-to-treat …
View source ↗ - Newsglobenewswire.com·69d ago·Neutral
Cardiff Oncology and Nerviano Medical Sciences Amend their 2017 Exclusive License Agreement SAN DIEGO and NERVIANO, Italy, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ: CRDF) ("Cardiff") and Nerviano Medical Sciences S.r.l.
View source ↗ - Newsglobenewswire.com·81d ago·Neutral
Cardiff Oncology to Participate in September 2026 Conferences SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that Mani Mohindru, Ph.D. will participate in two upcoming conferences.
View source ↗ - Newsglobenewswire.com·103d ago·Neutral
Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update Positive Phase 2 CRDF-004 data presented in an oral session at ASCO support advancement of 30 mg onvansertib plus FOLFIRI/bevacizumab into planned registrational program for first-line RAS-mutated mCRC
View source ↗
Earnings
Tue, Feb 23(in 3 months)
Consensus estimate $-0.15 per share
Typical surprise -5.3% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 12$-0.12 vs $-0.14beat
- Tue, Aug 11$-0.14 vs $-0.12miss
- Thu, May 14$-0.18 vs $-0.13miss
- Tue, Feb 24$-0.11 vs $-0.18beat
- Thu, Nov 6$-0.17 vs $-0.20beat
- Tue, Jul 29$-0.21 vs $-0.19miss
Estimates and results for CRDF via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CRDF officers and directors.
- Bought
- $4.2m
- Sold
- —
23 trades
0 trades
- Pace Gary Wbought
- Pace Gary Wbought
- Mohindru Manibought
- Mohindru Manibought
- Mohindru Manibought
- Pace Gary Wbought
- Pace Gary Wbought
- Pace Gary Wbought
77 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in CRDF.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
